ArticleOncology letters2026
FOXA2 enhances anoikis sensitivity in lung adenocarcinoma cells: Dual role of ABCA8 upregulation and NOX4 suppression.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the present study, the aim was to investigate the detailed mechanism of forkhead box protein A2 (FOXA2) in anoikis resistance in lung adenocarcinoma (LUAD). The levels of FOXA2 and ATP-binding cassette subfamily A member 8 (ABCA8) were assessed using public databases. The effects of overexpression (oe)-FOXA2, oe-nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and sh-ABCA8 on NOX4 levels, aggregation, cell viability, apoptosis and apoptosis-related proteins were analyzed using reverse transcription quantitative PCR, microscopy, MTT assays, flow cytometry and western blotting. Chromatin immunoprecipitation and dual-luciferase reporter assays were employed to determine the interaction between FOXA2 and ABCA8. In LUAD, FOXA2 and ABCA8 mRNA levels were downregulated, with lower expression observed in in A549 cells compared with BEAS-2B cells; this pattern was pronounced under suspension culture, where A549 cells showed a further decrease in FOXA2/ABCA8 expression alongside a marked increase in NOX4 expression, compared with adherent culture. Furthermore, oe-ABCA8 inhibited NOX4 expression and reversed the effects of oe-NOX4 on enhancing cell aggregation, promoting cell viability, decreasing apoptosis, suppressing cleaved caspase-3 expression and increasing NOX4 level in suspended A549 cells. Furthermore, FOXA2 bound to the ABCA8 promoter region and oe-FOXA2 reversed the effects of ABCA8 silencing on suspended A549 cells, including enhanced cell aggregation, increased cell viability, reduced apoptosis, suppressed cleaved caspase-3 expression and elevated NOX4 expression. Collectively, FOXA2 enhanced ABCA8 transcription, leading to inhibition of NOX4 expression and subsequently alleviating anoikis resistance in A549 cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.